^
Association details:
Biomarker:TP53 deletion
Cancer:Diffuse Large B Cell Lymphoma
Drug Class:Immunotherapy
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

17P (TP53) Deletion Determines Worse Survival in Diffuse Large B‑Cell Lymphoma Patients After First‑Line Treatment With Immunochemotherapy:A Retrospective Study of 151 Patients

Published date:
09/01/2023
Excerpt:
CONTRADICTING EVIDENCE: Del(17p) was independently and statistically significantly associated with worse overall survival (53% vs 76%, P<0.05), as well as IPI>2 (52% vs 82%, P<0.05)….Del(17p) was an independent predictor of survival in patients with DLBCL treated with first-line immunochemotherapy.
Secondary therapy:
Chemotherapy
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

FRONT-LINE RISK-ADAPTED THERAPY PRESENTED FAVORABLE OUTCOMESFOR YOUNG PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROMA CONSECUTIVE COHORT IN CHINA

Published date:
05/11/2023
Excerpt:
However, DH/TH and 17p/TP53 deletion were still associated with a poorer OS in the HR group ( P =0.004 and 0.014)….This is the first and largest single-center study in China to report the treatment of young DLBCL patients with risk- adapted therapy, in which IIC was applied to selected patients with clinically or biologically high-risk features and showed favorable results.
Secondary therapy:
Chemotherapy